Biosimilar Hormones Market Analysis 2024-2033 : Forecast Market Size, Top Segments And Largest Region | Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited

"The new report published by The Business Research Company, titled ""Biosimilar Hormones Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the biosimilar hormones market size has grown exponentially in recent years. It will grow from $3.9 billion in 2023 to $4.98 billion in 2024 at a compound annual growth rate (CAGR) of 27.5%. The biosimilar hormones market size is expected to see exponentially grown in the next few years. It will grow to $11.77 billion in 2028 at a compound annual growth rate (CAGR) of 24.0%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp

Rising Demand For Hormone Biosimilarsfueled By Prevalence Of Hormonal Deficiencies
The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years, and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market. For instance, in January 2022, according to the British Medical Journal, a UK-based peer-reviewed medical trade journal, the prevalence of GH deficiency (GHD) in children is thought to range from 1 in 3500 to 1 in 10000 across the globe. Also, in June 2022, according to a Medscape report, about 6,000 adults are expected to be diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the growth of the biosimilar hormones market.

Leading Biosimilar Hormones Manufacturers Forge Partnerships And Launch In Untapped Markets
Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launches in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products in various locations to boost sales and maximize profits. For instance, in February 2022, Alvotech Holdings S.A., a Luxembourg-based biopharmaceutical company specialising in the development of biosimilar medicines, announced partnerships with Fuji Pharma Co. Ltd., a Japan based pharmaceutical company, to develop biosimilar drug candidates in Japan. Through this partnership, both companies have decided to add new elements to their strategic alliance for the creation and marketing of biosimilar medicines in Japan.

The biosimilar hormones market covered in this report is segmented -

1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types
2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=3432&type=discount

Major companies operating in the biosimilar hormones market include Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Coherus BioSciences Inc., Alvotech, BioXpress Therapeutics, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt

Contents of the report:
1. Executive Summary
2. Biosimilar Hormones Market Report Structure
3. Biosimilar Hormones Market Trends And Strategies
4. Biosimilar Hormones Market - Macro Economic Scenario
5. Biosimilar Hormones Market Size And Growth
…..
27. Biosimilar Hormones Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.